Oral Anti-Inflammatory Peptide
Targeted Gut Health & Inflammatory Support
KPV is a naturally occurring tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH) that provides potent anti-inflammatory effects. Delivered in oral capsule form, KPV works directly in the GI tract to support gut health, reduce intestinal inflammation, and promote immune balance—ideal for those managing inflammatory bowel conditions, leaky gut, or chronic digestive issues.
250mcg
Per Capsule
Oral
Administration
1x
Daily Dosing
GI
Direct Action
Available Dosing
Medical-grade oral peptide therapy formulated for optimal bioavailability and GI tract targeting.
Standard therapeutic dose
Ideal For
Individuals seeking gut health support, managing IBD, IBS, or intestinal permeability, or looking for oral anti-inflammatory support without injections.
The Science
KPV is a tripeptide consisting of three amino acids: lysine-proline-valine. It is a C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH), a naturally occurring peptide in the body that plays a crucial role in immune regulation and anti-inflammatory signaling.
Unlike many peptides that require injection, KPV is uniquely suited for oral administration. When taken orally, KPV remains stable through the digestive tract and exerts its therapeutic effects directly at the site of GI inflammation—making it particularly valuable for intestinal health.
Research demonstrates KPV’s ability to inhibit inflammatory pathways, support intestinal barrier function, promote wound healing in the gut lining, and modulate immune responses without suppressing overall immune function. This makes it a targeted, well-tolerated option for chronic inflammatory conditions affecting the digestive system.
Book a Consultation
How It Works
KPV targets multiple inflammatory pathways to support gut health and immune balance.
As a derivative of α-MSH, KPV activates melanocortin receptors, triggering anti-inflammatory signaling cascades that reduce cytokine production and calm immune overactivity.
KPV directly inhibits nuclear factor kappa B (NF-κB), a key regulator of inflammatory gene expression, reducing the production of pro-inflammatory mediators in intestinal tissues.
Rather than broadly suppressing immunity, KPV selectively modulates inflammatory responses, supporting healthy immune tolerance in the gut while preserving protective immune function.
Clinical Benefits
Reduces intestinal inflammation and helps manage symptoms associated with IBD, IBS, Crohn’s disease, and ulcerative colitis through direct anti-inflammatory action.
Supports tight junction integrity and helps restore proper intestinal permeability, addressing leaky gut syndrome and improving nutrient absorption.
Promotes healing and regeneration of damaged intestinal tissue, supporting recovery from inflammation-related mucosal damage in the GI tract.
Modulates immune responses without suppression, helping establish oral tolerance and reducing inappropriate immune reactions to food and commensal bacteria.
Reduces bloating, discomfort, and digestive distress associated with chronic inflammatory conditions, improving overall quality of life and daily function.
While targeting the gut, KPV may also provide broader anti-inflammatory benefits throughout the body, potentially supporting joint health, skin conditions, and overall inflammation.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Comprehensive evaluation of your digestive health, symptoms, and treatment goals with our specialized physicians.
Custom KPV dosing plan designed for your specific condition, with consideration for timing and complementary therapies.
Pharmaceutical-grade KPV capsules shipped directly to your door with clear administration instructions.
Regular follow-up assessments to track symptom improvement, adjust dosing as needed, and optimize your outcomes.
Safety & Candidacy
KPV oral therapy is remarkably well-tolerated due to its natural origin and targeted mechanism. As a derivative of α-MSH, it works with the body’s existing regulatory systems rather than against them.
1x
Daily capsule administration—simple, convenient, and injection-free for consistent GI support
Natural
Derived from α-MSH, a peptide naturally found in the body that regulates inflammation and immune function
Questions
KPV is primarily used for inflammatory bowel conditions including Crohn’s disease, ulcerative colitis, IBS, and intestinal permeability (leaky gut). It may also support other inflammatory conditions affecting the gut lining, food sensitivities, and overall digestive health. Research suggests benefits for wound healing, immune modulation, and systemic inflammation as well.
KPV is uniquely suited for oral administration because it remains stable through the digestive tract and exerts its therapeutic effects directly in the GI system. This makes it ideal for gut-specific conditions. While many peptides require injection to avoid degradation, KPV’s mechanism actually benefits from oral delivery, targeting inflammation at the source in the intestinal lining.
KPV is typically taken once daily on an empty stomach—ideally first thing in the morning or between meals. This ensures maximum contact with the intestinal lining and optimal therapeutic effect. Your physician will provide specific timing recommendations based on your condition and treatment goals.
Response times vary by individual and condition severity. Some patients notice improvements in digestive comfort within 1-2 weeks, while more significant changes in inflammation markers and gut healing may take 4-8 weeks of consistent use. Our medical team monitors your progress and adjusts dosing as needed to optimize outcomes.
KPV is generally very well-tolerated with minimal side effects. Because it’s a naturally occurring peptide fragment, adverse reactions are rare. Some patients may experience mild digestive changes during the first few days as their body adjusts. Unlike immunosuppressive medications, KPV does not increase infection risk or cause systemic side effects.
KPV can often be used alongside other therapies, including conventional medications for IBD, probiotics, and nutritional supplements. However, it’s essential to discuss all current medications and supplements with your BHRC physician during your consultation to ensure safe and effective integration into your treatment plan.
Yes, KPV peptide therapy requires a prescription from a licensed physician. At BHRC, we conduct a comprehensive medical evaluation to determine if KPV is appropriate for your specific condition and health status. This ensures safe, effective treatment tailored to your individual needs.
Get Started
Schedule a consultation with our medical team to learn if KPV peptide therapy is right for your wellness journey.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. KPV peptide therapy is a compounded medication available by prescription only. Not all patients will respond to therapy, and individual results may vary. KPV should be used under medical supervision as part of a comprehensive treatment plan for inflammatory GI conditions. A consultation with our medical team and baseline evaluation are required to determine if this therapy is appropriate for you.
The question patients actually arrive with is not whether KPV works — it is whether they should be swallowing it or injecting it. That decision drives the outcome more than dose does, and it comes down to a single question: where do you need the peptide to act?
Oral is also simply more sustainable for many patients — a daily capsule gets taken consistently in a way that a daily injection often does not, and consistency is what separates protocols that work from protocols that were technically prescribed. For the full technical breakdown — dosing ranges, reconstitution math, syringe calculations and cycle structures — see our BPC-157 dosage guide.
Book a Oral KPV ConsultationResponse varies between individuals, and the timeline below reflects what patients on a supervised protocol commonly report rather than a guaranteed outcome. Your provider will set expectations specific to your labs, history and goals.
| Timeframe | What patients typically report |
|---|---|
| Weeks 1–2 | Usually little perceptible change. Some patients notice early shifts in bloating or stool consistency; this is variable and does not predict the final outcome. |
| Weeks 2–4 | The window in which responders most often notice something — typically reduced GI discomfort, urgency or bloating. |
| Weeks 4–6 | Changes tend to consolidate and become visible in structured symptom scoring rather than just in general impression. |
| Weeks 6–8 | Formal reassessment against baseline. Continue, taper or stop is decided here. |
| After the course | Many patients use oral KPV in defined courses around symptomatic periods rather than continuously. |
The genuinely useful comparison here is not KPV against other peptides — it is oral against injectable, and oral KPV against the other things patients consider for gut symptoms.
| Option | Primary use | Administration | Best suited to |
|---|---|---|---|
| Oral KPV | Local action along the GI tract | Capsule, daily | Gut-lining and GI inflammatory targets; patients who will not inject daily |
| Injectable KPV | Systemic anti-inflammatory signalling | Subcutaneous | Dermatologic and systemic inflammatory targets |
| Oral BPC-157 | Gut-lining repair | Capsule, daily | Repair-weighted gut protocols, often run alongside KPV |
| Glutamine / gut-support supplements | Substrate for intestinal cells | Oral powder or capsule | General gut support; widely available without prescription |
| Prescribed IBD therapy | Disease-modifying treatment | Varies | Diagnosed inflammatory bowel disease — not replaceable by peptides |
Oral KPV and oral BPC-157 are the pairing most often run together for gut protocols — KPV weighted toward inflammatory signalling, BPC-157 toward repair. Whether you need one, both or neither is a consultation decision.
Gut symptoms fluctuate week to week on their own, which makes them unusually easy to misread. Without structured scoring you cannot distinguish a real effect from a good fortnight.
At reassessment the question is simply whether the scores moved. If they did not, raising the dose or extending the course is rarely the answer, and your provider will discuss alternatives.
For gut targets, oral is generally the more appropriate route rather than a compromise — taken by mouth the peptide acts locally along the GI tract, which is exactly where you want it for inflammatory bowel symptoms. For systemic or skin targets, injectable KPV is the better choice. Neither route is universally superior; they suit different objectives.
Your provider sets this deliberately as part of the protocol, because timing relative to meals affects local exposure along the tract. It is not a detail worth improvising or copying from a forum — ask at your consultation and follow what you are given.
Yes, and it is a common gut-protocol pairing — KPV weighted toward inflammatory signalling, BPC-157 toward tissue repair. Each addition raises cost and complexity, so every element should have a stated reason. That decision is made in consultation after your history and current medications are reviewed.
Yes. BHRC prescribes and dispenses oral KPV under provider supervision following consultation. We do not supply it as an unsupervised product. Capsules sold online under ‘research use only’ labelling fall outside that framework and carry real sourcing, purity and legal risk.
Cost depends on course length and whether any lab work is required. Pricing is reviewed transparently at consultation before anything is prescribed. Peptide therapy is generally not covered by insurance.
No. Oral KPV is not a treatment for diagnosed inflammatory bowel disease and must not replace prescribed therapy. Some patients use it as a supervised adjunct alongside gastroenterology care, coordinated with their treating specialist. If you have IBD, that coordination is not optional.
No. KPV is not an FDA-approved drug in any formulation. It is accessed through compounding pharmacies and used off-label under provider supervision. Human research is limited relative to established medications, which is exactly why supervision and structured reassessment matter.
Patients who respond most often notice changes between weeks two and four, consolidating by weeks four to six. Formal reassessment is at four to eight weeks. If nothing has shifted by then, continuing is unlikely to change that.
Generally well tolerated. The most commonly reported issue is mild nausea or GI upset, which often settles with timing adjustments. Anything persistent, severe or unexpected should be reported to your provider promptly rather than waited out.
BHRC provides physician-supervised peptide therapy across its locations, including West Hollywood, West Los Angeles, Valencia, Paradise Valley and Summerlin. Consultation determines candidacy and route, with follow-up through your treating location.
If you are weighing the oral route against the alternatives, these are the pages that answer the comparison directly.
The literature below is peer-reviewed background on Oral KPV and the mechanisms discussed on this page. It is provided so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and much of it is preclinical — animal or cell-culture work that has not been replicated in humans. Your provider will discuss what the evidence does and does not support for your situation.
Dosage & Protocol Library
Oral KPV is commonly paired with gut and tissue-repair protocols. These guides cover exact dosing, reconstitution and cycling.
